Bristol Myers Squibb

News

Merck aims for first line kidney cancer use for Keytruda com...

Merck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing that it improved survival in combination with Pfizer’s Inlyta compared

News

BMS Opdivo fails in small cell lung cancer

Bristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with small cell lung cancer, who had relapsed following platinum-based chemother

News

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo.<

News

Cancer immunotherapy pioneers awarded Nobel medicine prize

Cancer immunotherapy pioneers James Allison and Tasuku Honjo have been awarded this year’s Nobel Prize in Physiology or Medicine.

News

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe

News

Merck aims for first line kidney cancer use for Keytruda com...

BMS Opdivo fails in small cell lung cancer

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

Cancer immunotherapy pioneers awarded Nobel medicine prize

EU regulators back Ipsen cancer drug in new liver cancer use

Top cancer doctor steps down from posts in industry affiliat...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks